Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02075281 · ClinicalTrials.gov registry record · Phase 2
Effect of LAPS-Exendin on Body Weight in Obese Population
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 297
- Enrollment target
NCT02075281 is a Phase 2 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 297 participants.
The verdict
NCT02075281, a Phase 2 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 297 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL HM11260C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 297 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02075281
The ClinicalTrials.gov registry entry for NCT02075281 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 297 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02075281 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02075281 about?
NCT02075281 is a clinical study titled "Effect of LAPS-Exendin on Body Weight in Obese Population". The purpose of this study is to determine the optimal dose and regimen of HM11260C, in combination with a hypocaloric diet, to reduce weight in obese subjects who are otherwise considered in stable health.
What is the current status of trial NCT02075281?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 297 participants. The study started on 2014-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT02075281?
The interventions under investigation include: Placebo (BIOLOGICAL), HM11260C (BIOLOGICAL).
Who is sponsoring clinical trial NCT02075281?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.